{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:34Z","timestamp":1792180654824,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400197"],"award-info":[{"award-number":["82400197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["L2510096"],"award-info":[{"award-number":["L2510096"]}]},{"name":"Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2025005"],"award-info":[{"award-number":["PX2025005"]}]},{"name":"Young Elite Scientists Sponsorship Program of the Beijing High Innovation Plan"},{"name":"Beijing Hospitals Authority Clinical medicine Development of special funding","award":["ZLRK202305"],"award-info":[{"award-number":["ZLRK202305"]}]},{"name":"Beijing Hospitals Authority \u201cDengfeng\u201d talent training plan","award":["DFL20240301"],"award-info":[{"award-number":["DFL20240301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax (VEN) combined with a hypomethylating agent (HMA) has become a standard-of-care frontline therapy for unfit patients with newly diagnosed acute myeloid leukemia (ND AML). The VIALE-A trial established the clinical benefit of VEN plus azacitidine (AZA), with a composite complete remission rate (CRc) of 66.4% and a median overall survival (OS) of 14.7 months. Nevertheless, remission durability remains heterogeneous, and the regimen is non-curative for many patients. Improving remission rates and long-term survival therefore remains an urgent unmet clinical need. VEN\/HMA-based triplet regimens incorporating targeted agents are emerging as promising strategies in ND AML, particularly FLT3 inhibitor\u2013based combinations reported at the 2025 American Society of Hematology (ASH) Annual Meeting. Notably, longer-term follow-up data from a study of gilteritinib plus VEN\/AZA in patients with ND FLT3-mutated AML showed a median OS of 29.7 months. Additional VEN\/HMA-based strategies, including combinations with menin inhibitors and other novel agents, are also being investigated. Here, we provide an overview of the latest clinical updates on VEN\/HMA-based triplet regimens in ND AML presented at the 2025 ASH Annual Meeting.<\/jats:p>","DOI":"10.1186\/s40164-026-00810-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:14:57Z","timestamp":1785143697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting"],"prefix":"10.1186","volume":"15","author":[{"given":"Haibo","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"Supplement 1","key":"810_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2025-45","volume":"146","author":"RS Azevedo","year":"2025","unstructured":"Azevedo RS, Daver N, Karrar O, DiNardo C, Kadia T, Yilmaz M, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood. 2025;146(Supplement 1):45. https:\/\/doi.org\/10.1182\/blood-2025-45.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1182\/blood-2025-654","volume":"146","author":"J Altman","year":"2025","unstructured":"Altman J, Perl A, Wang E, et al. Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (chemo): interim results from the phase 1\/2 VICEROY study. Blood. 2025;146(Supplement 1):654. https:\/\/doi.org\/10.1182\/blood-2025-654.","journal-title":"Blood"},{"key":"810_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-997","author":"RS Azevedo","year":"2025","unstructured":"Azevedo RS, Short N, Bataller A, Daver N, Kadia T, DiNardo C, et al. Phase I\/II study of decitabine\/cedazuridine (ASTX727), venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2025. https:\/\/doi.org\/10.1182\/blood-2025-997.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR4","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1182\/blood-2025-5226","volume":"146","author":"S Arora","year":"2025","unstructured":"Arora S, Kantarjian H, Maroun M, Borthakur G, Garcia-Manero G, Montalban-Bravo G, et al. A phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia. Blood. 2025;146(Supplement 1):5226. https:\/\/doi.org\/10.1182\/blood-2025-5226.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2025-47","volume":"146","author":"WY Jen","year":"2025","unstructured":"Jen WY, DiNardo C, Short N, Farhat A, El Hajjar G, Zhang B, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146(Supplement 1):47. https:\/\/doi.org\/10.1182\/blood-2025-47.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2025-766","volume":"146","author":"G Roboz","year":"2025","unstructured":"Roboz G, Wang E, Fathi A, Erba H, Pratz K, Guru Murthy GS, et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007. Blood. 2025;146(Supplement 1):766. https:\/\/doi.org\/10.1182\/blood-2025-766.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR7","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood-2025-1650","volume":"146","author":"J Watts","year":"2025","unstructured":"Watts J, Ragon B, Chandhok N, Sekeres M, Venugopal S, Johnston A, et al. Results of the phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy. Blood. 2025;146(Supplement 1):1650. https:\/\/doi.org\/10.1182\/blood-2025-1650.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood-2025-1649","volume":"146","author":"C Lachowiez","year":"2025","unstructured":"Lachowiez C, Kaempf A, Lehn C, Lundberg Williams T, Sheldon G, Leonard J, et al. Preliminary safety and efficacy results of a phase Ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML. Blood. 2025;146(Supplement 1):1649. https:\/\/doi.org\/10.1182\/blood-2025-1649.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2025-652","volume":"146","author":"S Garciaz","year":"2025","unstructured":"Garciaz S, Dumas PY, Peterlin P, Morillo D, Torregrosa Diaz JM, Ulrickson M, et al. \u03b39\u03b42 T-cell (\u03b39\u03b42TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): results from the phase 1\/2 study eviction. Blood. 2025;146(Supplement 1):652. https:\/\/doi.org\/10.1182\/blood-2025-652.","journal-title":"Blood"},{"issue":"Supplement 1","key":"810_CR10","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood-2025-1685","volume":"146","author":"L Liu","year":"2025","unstructured":"Liu L, Yang L, Chen F, Chang L, Zhao L, Zhou X, et al. Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open-label prospective study. Blood. 2025;146(Supplement 1):1685. https:\/\/doi.org\/10.1182\/blood-2025-1685.","journal-title":"Blood"},{"issue":"12","key":"810_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"issue":"21","key":"810_CR12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373. https:\/\/doi.org\/10.1182\/blood.2024025409.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00810-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00810-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00810-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:13:19Z","timestamp":1785514399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00810-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00810-3","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is not applicable for this summary.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}